Demand in the Lewy body dementia treatment market depends on who is treated, how medicines reach patients and where healthcare investment is rising. Polaris Market Research projects the market to grow from USD 6.61 billion in 2025 to USD 13.32 billion by 2034, registering a CAGR of 8.1%. An aging population is contributing to higher diagnosis rates, and awareness of dementia-related conditions is rising across regions.

Indication Segments

By indication, the market is segmented into Parkinson’s disease and dementia with Lewy bodies (DLB). The Parkinson’s disease segment accounted for a major share in 2024 because of overlapping pathological mechanisms and symptoms with Lewy body dementia, which creates demand for treatments that address both conditions. The increasing geriatric population, advancements in treatment options and growing awareness are supporting the segment’s expansion, as is growing awareness of Parkinson’s disease treatment among people.

The dementia with Lewy bodies segment is experiencing significant growth as increased recognition and diagnosis lead to higher demand for targeted therapies. Advances in diagnostic techniques and a better understanding of the clinical presentation of DLB have also contributed to the segment’s expansion.

Distribution Channels

By distribution channel, the market covers drug stores, hospital pharmacies, online pharmacies and retail pharmacies. Online pharmacies emerged as the dominant channel in 2024, reflecting the convenience of obtaining medications from home, a shift accelerated by the COVID-19 pandemic, which increased reliance on digital channels for purchasing medications, including those for chronic conditions like Lewy body dementia. These platforms often provide competitive pricing, discounts and a broader range of products than traditional stores, along with easy access to prescriptions and informational resources, which enhance the overall patient experience.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/lewy-body-dementia-treatment-market

Hospital pharmacies continue to play a significant role because of specialized healthcare professionals, a comprehensive range of medications and the need for hospital-based diagnostic and treatment services. A substantial proportion of patients receive their diagnoses and initial treatments in hospital settings, which underscores the importance of timely access to necessary medications and integrated care. Digital marketing initiatives and patient support programs further contribute to market growth.

Regional Analysis

North America holds the largest share on the strength of its patient population, awareness and advanced healthcare infrastructure, supported by government and private investment in neurological research. Europe is growing as an aging population and rising awareness of neurodegenerative disorders encourage adoption of innovative therapeutic approaches, helped by advanced healthcare infrastructure and a strong emphasis on research and development. Norway is expected to register the highest CAGR from 2025 to 2034, reflecting proactive healthcare strategies and investment in dementia care.

Asia Pacific is emerging as a rapidly growing market because of a large and aging population, increasing healthcare expenditure and heightened awareness of dementia-related conditions. India is anticipated to exhibit the highest CAGR from 2025 to 2034, driven by improvements in healthcare infrastructure and a greater focus on neurological disorders.

Growth Strategy and Recent Developments

Growth strategies focus on expanding research and development, securing regulatory approvals and forming collaborations to enhance treatment accessibility. Awareness campaigns and physician education programs help drive early diagnosis and treatment adoption, while expanding distribution networks, particularly in emerging markets, supports broader patient access. In August 2025, the Cleveland Clinic announced its participation in the Davos Alzheimer’s Collaborative Accurate Diagnosis Project, which aims to establish a pathway for more accurate and timely diagnosis of Alzheimer’s disease.

Key Players in the Lewy Body Dementia Treatment Market

•         AbbVie Inc.

•         AstraZeneca plc

•         Bristol-Myers Squibb Company

•         Eisai Co., Ltd.

•         Eli Lilly and Company

•         F. Hoffmann-La Roche Ltd

•         GlaxoSmithKline plc

•         Johnson & Johnson

•         Merck & Co., Inc.

•         Novartis AG

•         Otsuka Pharmaceutical Co., Ltd.

•         Pfizer Inc.

•         Sanofi S.A.

•         Takeda Pharmaceutical Company Limited

•         UCB S.A.

Conclusion

The Lewy body dementia treatment market is shaped by indication, access and geography. The Parkinson’s disease indication retains a major share while dementia with Lewy bodies grows on better recognition; online pharmacies lead distribution while hospital pharmacies remain central to diagnosis and initial treatment; and rising awareness of neurodegenerative disorders is lifting regional prospects, particularly in Norway and India. Together these factors support the projected CAGR of 8.1% through 2034.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market